BioCryst Pharmaceuticals Files 8-K on Financials
Ticker: BCRX · Form: 8-K · Filed: Aug 5, 2024 · CIK: 882796
Sentiment: neutral
Topics: financial-results, disclosure
Related Tickers: BCRX
TL;DR
BioCryst dropped an 8-K on financials, check it out.
AI Summary
BioCryst Pharmaceuticals, Inc. filed an 8-K on August 5, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements. The company is incorporated in Delaware and its principal executive offices are located in Durham, North Carolina.
Why It Matters
This 8-K filing provides investors with crucial updates on BioCryst Pharmaceuticals' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any immediate, significant risks.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- August 5, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Durham, North Carolina (location) — Principal Executive Offices
- 919-859-1302 (phone_number) — Registrant's telephone number
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' but does not detail specific figures within the provided text.
Are there any new material events or disclosures mentioned in this 8-K?
The filing covers 'Results of Operations and Financial Condition', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits', suggesting updates but specific events are not detailed in the provided text.
What is the primary purpose of this 8-K filing for BioCryst Pharmaceuticals?
The primary purpose is to report on the company's results of operations and financial condition, along with any Regulation FD disclosures and financial statements.
When was this 8-K filing submitted?
The filing was submitted on August 5, 2024.
Where are BioCryst Pharmaceuticals' principal executive offices located?
BioCryst Pharmaceuticals' principal executive offices are located at 4505 Emperor Boulevard, Suite 200, Durham, North Carolina 27703.
Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-08-05 07:05:05
Filing Documents
- f8k_080524.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 100KB
- 0001171843-24-004422.txt ( ) — 321KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_080524_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 5, 2024, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing recent corporate developments and its financial results for the second quarter ended June 30, 2024, which also referenced a conference call and webcast to discuss these recent corporate developments and financial results. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein. The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated August 5, 2024 entitled "BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioCryst Pharmaceuticals, Inc. Date: August 5, 2024 By: /s/ Alane Barnes Alane Barnes Chief Legal Officer